Nasdaq-listed, Israel-headquartered biotechnology company MediWound Ltd. is trying to revolutionize the methods doctors treat second and third-degree burns. It is using a patented technology first discovered by a German military doctor during World War II, which involves the topical application of pineapple plant enzymes to burn wounds.
Founded in 2001 in Yavne, 18 miles south of Tel Aviv, MediWound is the developer, manufacturer who commercialize treatments for severe burns and chronic wounds.
The company’s flagship product is a pineapple enzyme-based treatment used for the removal of dead tissue from burn wounds called NexoBrid.
The gel preparation kit is compiled of two vials, one containing enzymes from powdered pineapple tree trunks, the other containing a water-based gel. The two are designed to be combined just before application on the skin. The gel is effective in removing only the dead tissue, possibly minimizing the need for surgical procedures.
MediWound CEO Gal Cohen narrates that, German military doctor called Jerry Klein who was stationed in North Africa in World War Two. In US He met an American doctor, and the two began collaborating in the research of the medicinal properties of pineapple enzymes when applied to burns.
The research evolved throughout the 1960s and 1970s, but the two were unable to isolate and control the levels of enzymes well enough to assure a consistent, marketable medication can be produced.
Israeli plastic surgeon Lior Rosenberg took on Mr. Klein’s research after meeting him at a conference in Switzerland in the 1980s. For over two decades Mr. Rosenberg researched and experimented with pineapple enzyme-based treatments and in 2001 he founded MediWound.
"It took us 12 years from the moment we founded the company to receive marketing approval," Gal Cohen, Mediwound CEO said. NexoBrid was approved for marketing in Europe in 2012 and Israel in 2013.
NexoBrid is intended as a replacement for surgical procedures. There are no other non-surgical treatments that achieve what NexoBrid does, Mr. Cohen said. Since the 1970s, doctors learned that the only way to treat severe burns is to surgically remove the dead tissue. "We are trying to change a medical paradigm, and that is a great challenge," Mr. Cohen added.
NexoBrid had its moment in the spotlight in October 2015, when more than 150 people suffered severe burns following a fire at a Bucharest, Romania nightclub. MediWound sent two doctors and a supply of NexoBrid kits to aid local doctors.
"The aid Mediwound sent Romania was practical proof of NexoBrid’s ability to serve as a central treatment for multi-casualty events," said Mr. Cohen, who added that NexoBrid was used to treat over 50 burn victims in just three days.
More than half of the burn centers in European hospitals now use NexoBrid, Mr. Cohen said.In January, Mediwound announced its expansion into Latin America through an exclusive agreement with Avalon Pharmaceutical S.A.
MediWound will announc an agreement with Taiwan, Chinaese biotech company Holy Stone Healthcare, Co., Ltd. for the distribution of NexoBrid in Taiwan, China. The companies plan to commercialize NexoBrid in Taiwan, China after getting regulatory approvals, expected to be granted within two years.
"This agreement is part of our strategy to expand the use of NexoBrid to international markets by collaborating with local companies that take the responsibility for and possess the expertise in local regulatory, market access and marketing efforts," said Gal Cohen.
"Evidenced-based clinical studies and growing experience reported by numerous experts treating patients in routine and mass casualty events demonstrate that NexoBrid will play a major role in the future of burn care," said Albert Wu, Chief Executive Officer of Holy Stone.
In addition to Europe and South America, NexoBrid is also marketed in Japan, South Korea, and India.
...
(All Rights Reserved)